BACKGROUND AND OBJECTIVES: Arginine vasopressin (AVP), an endogenous hormone with vasopressor properties, may be inadequately secreted during episodes of intradialytic hypotension (IDH). DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: To evaluate this, we performed a prospective, observational pilot study of 20 chronic hemodialysis patients assessing the baseline AVP level and trend of AVP with ultrafiltration in patients with a diagnosis of IDH compared with patients without IDH. Ten symptomatic IDH patients and 10 controls were enrolled and matched for age, gender, and dialysis vintage. AVP levels were obtained hourly throughout the dialysis session and during hypotensive episodes. RESULTS: We observed that IDH patients experienced greater decreases in both systolic and diastolic blood pressure during the dialysis session despite equivalent ultrafiltration in both groups. AVP concentration did not increase in the IDH patients (5.0 +/- 1.8) compared with controls (6.4 +/- 6.0) (P = 0.5) despite hypotensive events. CONCLUSIONS: This study suggests that symptomatic IDH patients are unable to mount an appropriate increase in AVP secretion in the setting of hypotension. These findings support the possibility of AVP as a mechanism driven therapy for patients with symptomatic IDH.
BACKGROUND AND OBJECTIVES:Arginine vasopressin (AVP), an endogenous hormone with vasopressor properties, may be inadequately secreted during episodes of intradialytic hypotension (IDH). DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: To evaluate this, we performed a prospective, observational pilot study of 20 chronic hemodialysis patients assessing the baseline AVP level and trend of AVP with ultrafiltration in patients with a diagnosis of IDH compared with patients without IDH. Ten symptomatic IDH patients and 10 controls were enrolled and matched for age, gender, and dialysis vintage. AVP levels were obtained hourly throughout the dialysis session and during hypotensive episodes. RESULTS: We observed that IDH patients experienced greater decreases in both systolic and diastolic blood pressure during the dialysis session despite equivalent ultrafiltration in both groups. AVP concentration did not increase in the IDH patients (5.0 +/- 1.8) compared with controls (6.4 +/- 6.0) (P = 0.5) despite hypotensive events. CONCLUSIONS: This study suggests that symptomatic IDH patients are unable to mount an appropriate increase in AVP secretion in the setting of hypotension. These findings support the possibility of AVP as a mechanism driven therapy for patients with symptomatic IDH.
Authors: N E Armengol; A Cases Amenós; M Bono Illa; J Calls Ginesta; J Gaya Bertrán; F R Rivera Fillat Journal: Nephrol Dial Transplant Date: 1997-02 Impact factor: 5.992
Authors: Stefan Jochberger; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Barbara Friesenecker; Andreas J Mayr; Martin W Dünser Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: B Heintz; K Reiners; U Gladziwa; R Kirsten; K Nelson; D Wieland; J Riehl; H Mann; H G Sieberth Journal: Clin Nephrol Date: 1993-04 Impact factor: 0.975
Authors: Sarah Chung; Hye Seon Jeong; Dae Eun Choi; Hee-Jung Song; Young Gi Lim; Joo Yeon Ham; Ki Ryang Na; Kang Wook Lee Journal: J Korean Med Sci Date: 2016-05-19 Impact factor: 2.153